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Abstract
OBJECTIVE: To provide survival estimates of peo-
ple living with human immunodeficiency virus (PL-
HIV) after treatment with Traditional Chinese Medi-
cine (TCM) in rural China, to identify the prognostic
factors at enrollment, and to explore the effective-
ness of TCM in treating PLHIV.
METHODS: PLHIV who enrolled in national TCM
HIV treatment trial program in October 2004 were
analyzed in this study and followed up to October
2010. Survival time was estimated by the Ka-
plan-Meier curve and hazard ratios, and identifying
prognostic factors were computed through Cox
proportional hazard models.
RESULTS: A total of 1666 PLHIV were included with
102 591 person-months of follow-up. Overall, 312
(18.7%) patients died. The total mortality rate over
the study period was 3.6 per 100 person-years,
which was lower than the worldwide rate. The cu-
mulative survival rate was 95.9% at 1 year [95% con-
fidence interval (CI ) (94.8-96.8)] and 80.4% at 6
years [95% CI (78.4-82.3)]. Elevated death risks
emerged among males, older individuals, and
those with lower CD4+ T-cell counts.
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CONCLUSION: TCM could increase survival and
lengthen the life span of PLHIV in Henan province
of China, as shown by our retrospective cohort
study. Factors such as sex, age, education, and
CD4+ T-cell counts correlated to survival. However,
retrospective cohorts bias the data, so more pro-
spective studies should be performed to confirm
our primary results.
© 2014 JTCM. All rights reserved.
Key words: Retrospective studies; HIV; Acquired im-
munodeficiency syndrome; Survival; Medicine, Chi-
nese traditional
INTRODUCTION
By the end of 2009, the estimated number of people
living with human immunodeficiency virus (HIV) in
China was 740 000 (560 000-920 000). Among those
patients, 105 000 had acquired immune deficiency syn-
drome (AIDS) (97 000-112 000).1 Since 2003, China
has progressively increased funding to support the free
combined antiretroviral treatment (cART) plan for
people diagnosed with HIV.1 This has resulted in de-
creased morbidity and mortality, but the prevalence of
HIV-related and non-HIV-related diseases and symp-
toms has increased in HIV-infected patients. These un-
predictable or embarrassing symptoms include nausea,
diarrhea, fatigue, lipodystrophy, and skin problems,
and may result in patients not adhering to the cART.2-4
The side effects of cART and incurable diseases compel
researchers to find new drugs or complementary treat-
ments. One type of complementary and alternative
medicine, Traditional Chinese Medicine (TCM), has
been used for thousands of years for many diseases,
and in the last 30 years has been used to treat HIV.
TCM use for HIV/AIDS has been partially shown to
reduce plasma HIV viral load, increase CD4 + T-cell
counts, promote immunity reconstitution, ameliorate
symptoms and signs, improve health-related quality of
life (HRQOL), and counteract against the effects of an-
ti-retroviral drugs.5
In 2004, the National Administration of Traditional
Chinese Medicine in China started a national TCM
HIV treatment trial program (NTCMTP), which even-
tually provided free TCM treatment to 9267 people
living with human HIV (PLHIV) in 17 provinces (au-
tonomous regions and municipalities) by the end of
2009.1 During the treatment program, PLHIV report-
ed that their clinical symptoms (e.g., fatigue, pain,
sleep disturbance, shortness of breath, coughing) were
greatly relieved, and opportunistic infections decreased
significantly.6-8 However, the long-term clinical bene-
fits of TCM treatment for PLHIV are unclear. There-
fore, survival analysis of PLHIV after treatment with
TCM was used to explore a possible curative effect.
The objective of our analysis was to document the out-
come of TCM treatment in terms of survival and its de-
terminants through a retrospective cohort study.
MATERIALS ANDMETHODS
Context
The Henan NTCMTP center, from which the data in
this study was provided, treated the PLHIV in the
Henan province of China. All PLHIV in this area com-
prised mostly one ethnic group, and resided in the
countryside. The prevalence of HIV infection caused
by paid blood donation was high, and the prevalence
in the whole population of this area was 9.1%.9 The in-
fection rate in some villages was up to 35.87% .10 Be-
cause of a lack of a recent negative HIV antibody test
date of patients, we had to infer infection date accord-
ing to the character of the epidemic in each area. Epi-
demiological study found that HIV transmission was
mostly associated with the sale of blood plasma. Illegal
blood supply practices started from the end of 1993,
peaked in 1994, and were prohibited in March 1995.11
From the date and location of the high risk behavior,
such as blood sale or blood transfusion, we inferred the
HIV infection date.
Patients
All PLHIV older than 18 years enrolled in NTCMTP
in October 2004 were eligible for this retrospective
study, and they were followed up to October 2010.
Their data were collected at enrollment and monthly
thereafter, mainly through a case report form, which in-
cluded demographic information, laboratory measure-
ments (i.e., CD4 + T-cell counts, whole blood cell
counts, urine analysis, liver and renal function, and
HIV viral load test results), details of therapy, clinical
symptoms, and vital status. Once the PLHIV did not
return to get his or her medicine, medical workers
would actively visit his or her neighbor or relative to
identify whether the patient had died or was lost to fol-
low-up. If patients died of a non-AIDS-defining ill-
ness, this was considered "lost to follow-up."
Data analysis
Since the start of the program in this area, all PLHIV
data was entered in an ACCESS database. When
CD4 + T-cell counts were unavailable, we recorded
them as a separate category in the model. Patients in-
fected with HIV through blood sale and blood transfu-
sions were recorded as "blood donor" and "blood recip-
ient." Patients infected with HIV through sexual inter-
course or unknown routes were recorded as "others."
Survival time was calculated from the date of PLHIV
enrolment in NTCMTP to the date of death or Octo-
ber 2010. Survival rate after receiving TCM treatment
was estimated by Kaplan-Meier curves. Survival curves
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for subgroups were compared by the Log-Rank test. A
multivariate Cox proportional hazards model12 was
used to identify factors present at enrollment that were
associated with the risk of death after TCM treatment.
Multivariate hazard ratios (HR), with their 95% confi-
dence intervals (CI), were computed after adjustment
for factors that turned out to be statistically significant
after univariate analysis. All statistical analyses were per-
formed by using SPSS 19.0 (SPSS Inc., Chicago, IL,
USA). Two-sided P-values less than 0.05 were consid-
ered to indicate statistical significance.
Ethical considerations
This study was approved by the institutional review
board of the first hospital affiliated to Henan Universi-
ty of Traditional Chinese Medicine. Individual in-
formed consent was not achieved because this analysis
used currently existing data collected during the course
of routine treatment, and the data were reported in ag-
gregate without the use of individual identifying infor-
mation.
RESULTS
We studied 1666 PLHIV older than 18 years who en-
rolled in the national TCM HIV treatment trial pro-
gram in October 2004. Among them, the median age
was 40 years [interquartile range (IQR), 36-48] and
50.0% were males. Overall, 616 (37.7%) patients had
never had formal education. The majority of PLHIV
(1293/1666, 77.6%) were infected through blood sale,
whereas 323 (19.4%) and 34 (2.1%) of PLHIV were
infected through blood transfusion and sexual inter-
course, respectively. Median CD4+ T-cell counts at en-
rollment were 301 cells/µL (IQR, 187-439) and 439
(26.4%) patients had CD4+ T-cell counts <200 cells/µL.
Of the 1666 PLHIV, there were 102 591 per-
son-months of follow-up, and 1223 (73.4% ) PLHIV
were still under follow-up in October 2010, while 312
(18.7%) PLHIV died, and 131 (7.9%) were lost to fol-
low-up. Of the 131 patients lost to follow-up, 6
(4.6% ) exited because of disease aggravation, 74
(56.5% ) moved for work, 25 (19.1% ) died of
non-AIDS-defining illnesses such as suicide or acci-
dent, and 26 (19.8% ) were removed without reason.
Total mortality rate over the study period was 3.6 per
100 person-years. The mortality rates were 4.30, 3.49,
387, 3.87, 3.68, 4.39, and 2.53 per 100 person-years
in the first, second, third, fourth, fifth and sixth years
of TCM treatment, respectively (Figure 1). A decrease
in mortality was observed over the 6-year follow-up, ex-
cept an increase in 2009. Although the mortality in-
creased slightly in 2009, the rate remained lower than
the world HIV mortality rate for every year.13
95.9% [95% CI (94.8, 96.8)] of PLHIV were alive af-
ter 1 year and 92.7% [95% CI (91.3, 93.9)] after 2
years, while 80.4% [95%CI (78.4, 82.3)] PLHIV sur-
vived 6 years after receiving TCM treatment (Figure
2). The median survival time was more than 6 years.
Survival was lower for males than females (P<0.05),
and similar in "blood donor" and "blood recipient" (P=
0.061). More highly educated PLHIV had a higher sur-
vival rate (P<0.05). Older PLHIV and those with low-
er CD4+ T-cell counts had a higher mortality risk (P<
0.05).
Table 1 shows the results of the multivariate analysis of
factors associated with mortality of PLHIV after TCM
treatment. Sex, age, education, and CD4 + T-cell
counts at enrollment were related with mortality. Ad-
justing for other factors, the mortality risk of males was
1.5 times that of females [HR: 1.57, 95% CI (1.25,
1.97)]. Education level was also associated with mortal-
ity, and more highly educated patients had a lower risk
than those with little education [HR: 0.79, 95% CI
(0.63, 0.99)]. Patients aged between 40 and 44 had a
1.6 times higher risk of death than those younger than
34 [HR: 1.69, 95% CI (1.13, 2.52)]. This risk was in-
creased two-fold for those older than 50 years. PLHIV
with CD4+ T-cell counts <200 cells/µL had a mortali-
ty risk nearly five-fold as much as those with >350
cells/µL [HR: 4.63, 95% CI (3.30, 6.48)], whereas
CD4 + T-cell counts between 200 and 350 cells/µL
had twice the mortality as those with >350 cells/µL
[HR: 2.27, 95% CI (1.58, 3.26)].
DISCUSSION
80.43% of PLHIV survived 6 years after receiving
TCM treatment. Therefore, the median survival time
cannot be calculated. Patients infected with HIV in
our analysis were associated mostly with commercial
plasma donation. Most studies reported that the medi-
an incubation period for HIV progression to AIDS
was 8-9 years among former commercial plasma do-
nors in China.14-16 Therefore, we inferred that the pa-
Figure 1 Mortality in this study vsworldwide data
(years)
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tients in this region had AIDS and AIDS-defined
death in 2004, when the NTCMTP started. In this fol-
low-up analysis, the median survival time of PLHIV
was longer than 6 years, plus the 10 years of infection
time before PLHIV received TCM treatment. There-
fore, half of the PLHIV enrolled in this program lived
more than 16 years after HIV infection, which is lon-
ger than those without treatment.17 Overall, 131
Factor
Sex
Age (years)
Education (years)
CD4+T cell (cells/μL)
Female
Male
23-34
35-39
40-44
45-49
50-68
≤6
>6
>350
200-350
<200
Unavailable
Cases (n)
833
833
333
412
345
256
320
770
896
439
501
621
105
Deaths (n)
131
181
43
59
61
59
90
160
152
128
81
46
57
HRa (95% CI)
1b
1.57 (1.25, 1.97)
1b
1.13 (0.76, 1.68)
1.28 (0.86, 1.90)
1.69 (1.13, 2.52)
2.19 (1.52, 3.16)
1b
0.79 (0.63, 0.99)
1b
2.27 (1.58, 3.26)
4.63 (3.30, 6.48)
31.47 (20.77, 47.69)
P value
-
0.001
-
0.549
0.231
0.010
0.001
-
0.045
-
0.001
0.001
0.001
Table 1 Distribution of 1666 PLHIV after TCM treatment with HRs of death and 95% CIs
Notes: PLHIV: people living with human immunodeficiency virus; TCM: Traditional Chinese Medicine; HR: hazard ratio; CI: confi-
dence interval. aregression model adjusted for sex, age, education and CD4+ T-cell count; breference category.
Figure 2 Cumulative survival after TCM treatment
A: overall; B: sex; C: age; D: education; E: HIV transmission category; F: CD4 T cells counts. TCM: Traditional Chinese Medicine;
HIV: human immunodeficiency virus.
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(7.9%) PLHIV were lost to follow-up in this analysis,
of which only 6 (4.6%) PLHIV exited because of dis-
ease aggravation. Conversely, most patients left to
work because the TCM had improved their clinical
symptoms. Therefore, we think that TCM therapy
could reduce the mortality of PLHIV and lengthen
their lives.
Compared with the free antiretroviral treatment plan
in China, which showed the mortality rate of adults
with AIDS was 5 per 100 person-years after 6 months
of receiving treatment,1 the mortality rate in our study
was lower. In fact, the total mortality rate over the
study period was 3.6 per 100 person-years. The mortal-
ity rates were 4.30, 3.49, 387, 3.87, 3.68, 4.39, and
2.53 per 100 person-years in the first, second, third,
fourth, fifth, and sixth years of TCM treatment, respec-
tively, which were also lower than UNAIDS reports.13
The survival of PLHIV has been dramatically pro-
longed by the use of cART,18,19 but mortality in other
areas has noticeable differences.20-22 Older age, gender,
lower CD4 + T-cell counts, HIV transmission routes,
education, economic level, race, ethnicity, and malnu-
trition are all risk factors for death.23-27
In our analysis, the mortality risk of PLHIV with
CD4+ T-cell counts <200 cells/µL was nearly five-fold
that of those with >350 cells/µL, whereas the CD4 +
T-cell counts between 200 and 350 cells/µL was twice
that of those with >350 cell/µL. Similar to older age,28,29
lower CD4+ T-cell count is an independent risk factor
for death, which has been shown previously.30 Despite
the dramatic decline in AIDS mortality that followed
the introduction of cART, women benefited less from
this intervention and had a higher mortality risk than
men.31 However, the mortality risk of men was
1.5-fold that of women after adjusting for other factors
in our analysis, which suggests that women can benefit
more from TCM. In our analysis, higher education
was associated with a lower mortality risk with no dif-
ference in HIV transmission routes.
The advent of cART gave hope to millions of HIV/
AIDS sufferers because it dramatically reduced disease
progression and death. However, these benefits were
only achieved with high levels of adherence,32 and less
than optimal adherence was associated with virological
failure.33 Failure to adhere potentially increased the risk
of developing treatment-resistant strains of HIV.34-36
Additionally, toxicity and discomfort caused by the
medications37-39 could result in patients being nonadher-
ent to medications.35 There are many reports about
cART resistance.40-44 Moreover, resistant strains can be
transmitted to other individuals, thereby decreasing
treatment options and potentially exacerbating the
HIV epidemic.45 Although this clinical dilemma re-
stricts the effectiveness of cART, it may be solved by
TCM.
Recent studies have indicated that, even in the cART
era, mortality rates among HIV-infected people are
still at least four times those of the general popula-
tion.46,47 Therefore, there is room for improvement,
and we need to explore new approaches to improve pa-
tient quality of life and decrease the mortality rate of
PLHIV. TCM may be able to improve quality of life
and relieve the clinical symptoms of PLHIV. Our anal-
ysis found that TCM could increase survival of PL-
HIV, though more research is needed to clarify the
mechanisms of TCM in decreasing mortality.
In conclusion, our retrospective cohort study found
that TCM could increase survival and lengthen life
span in PLHIV in Henan province of China. Factors
such as sex, age, education, and CD4+ T-cell counts re-
lated to survival. However, the limitations of retrospec-
tive cohort study bias this study, so more prospective
studies are necessary to confirm our primary results.
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